Specifications of predominant nonserious adverse events days 1–3 after intrathecal gadobutrol in various dosesa
| iNPH Cohort | Non-iNPH Cohort | ||||
|---|---|---|---|---|---|
| 0.50 mmol (n = 21) | 0.25 mmol (n = 94) | 0.10 mmol (n = 29) | 0.50 mmol (n = 35) | 0.25 mmol (n = 17) | |
| No adverse events (No.) (%) | 9 (42.9%) | 62 (66.0%) | 26 (89.7%) | 17 (47.2%) | 5 (29.4%) |
| Adverse events present (No.) (%) | 12 (57.1%) | 32 (34.0%) | 3 (10.3%) | 18 (51.4%) | 12 (70.6%) |
| Predominant adverse events | |||||
| Mild headache, nausea, and/or dizziness (No.) (%) | 2 (9.5%) | 17 (18.1%) | 1 (3.4%) | 3 (8.3%) | 2 (11.8%) |
| Moderate headache, nausea, and/or dizziness (No.) (%) | 5 (23.8%) | 4 (4.3%) | 1 (3.4%) | 8 (22.9%) | 6 (35.3%) |
| Severe headache, nausea, and/or dizziness (No.) (%) | 1 (4.8%) | 1 (1.1%) | 0 | 4 (11.1%) | 0 |
| Back pain from spinal puncture (No.) (%) | 2 (9.5%) | 5 (5.3%) | 1 (3.4%) | 3 (8.6%) | 3 (17.6%) |
| Other (No.) (%) | 2 (9.5%) | 5 (5.3%) | 0 | 0 | 1 (5.9%) |
↵a Data are presented as the number of individuals (percentages are in parentheses).